

## EUROPEAN PATENT VALIDATED FOR CORE LUNG AND COLORECTAL CANCER PATENT FAMILY

- **European Patent No 2606358 granted**
- **EP2606358 validated in France, Germany, Italy, Spain, Switzerland and UK**
- **BARD1-Lung cancer test now protected by multiple granted patents in the US, Europe, Japan, China, Israel and Australia**

**Perth, Australia, 3 June 2019:** BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company), a medical technology company developing non-invasive cancer diagnostics, today announced that it has received confirmation from the European Patent Office (EPO) that granted European Patent no 2606358 entitled “BARD1 isoforms in lung and colorectal cancer and use thereof” has now been validated in France, Germany, Italy, Spain, Switzerland and United Kingdom.

European Patent no 260663 was granted by the EPO on 26 December 2018. However, EP patents are not enforceable until validation has been completed in the designated countries. EP260663 has now been validated in France, Germany, Italy, Spain, Switzerland and United Kingdom, providing enforceable IP protection in these countries.

This patent family (PCT/IB2011/053635) protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms and a method for treating and/or preventing lung cancer and colorectal cancer. The granted EP260663 claims are directed towards lung cancer. The patent application was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17 August 2011 and is due to expire on 17 August 2031. BARD1 LSL (via its fully owned subsidiary BARD1AG SA) has an exclusive global license to the commercial rights to this intellectual property from UNIGE/HUG.

BARD1 CEO Dr Leeorne Hinch said: “This core patent family provides intellectual property protection for our BARD1-Lung cancer test in development for early detection of lung cancer. It now has 8 granted patents in the US, Europe, Japan, China, Israel and Australia, with other jurisdictions pending.”

- ENDS -

### FOR MORE INFORMATION PLEASE CONTACT:

**Dr Leeorne Hinch**  
CEO  
E [leeorne@bard1.com](mailto:leeorne@bard1.com)  
M +61 400 414 416

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

### ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1’s vision is to detect cancer early and save lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

## ABOUT THE BARD1 INTELLECTUAL PROPERTY PORTFOLIO

BARD1 has established a strong intellectual property (IP) position protecting its biomarker technology platform and products with claims covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The Company owns or exclusively licenses 5 patent families with 12 granted and 18 pending patents covering its technology, products and uses in the US, Europe, China, Japan and other countries.

Figure 1: BARD1 Patent Status

Patent Family	Title	Granted	Pending	Expiry
PCT/FR01/02731	Truncated BARD1 protein and its diagnostic and therapeutic uses	US, JP		2021
PCT/IB2011/053635	BARD1 isoforms in lung and colorectal cancer and use thereof	US, EP, JP, JP div, CN, CN div, IL, AU	US divisional, CA, BR, SG, HK	2031*
PCT/IB2011/054194	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof	US	US divisional, EP	2031*
PCT/EP2014/073834	Lung Cancer Diagnosis		US, EP, CA, JP, IL, CN, AU, SG, KR, HK	2034*
10,273,475	Regulation of BARD1 expression by non-coding RNA	US	US continuation	2035

\* Plus any extension of term in the US due to prosecution delay

## DISCLAIMER

This announcement contains “forward-looking statements” and “forward-looking information”, including statements and forecasts relating to the Company. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “is expecting”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might”, or “will” be taken, occur or be achieved. Such information is based on assumptions and judgements of management regarding future events and results. The purpose of forward-looking information is to provide the audience with information about management’s expectations and plans. Readers are cautioned that forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company and/or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information.